Top 100 Contractors in NAICS 325412: Pharmaceutical Preparation Manufacturing, FY2024

Parent companies by net contract obligations Oct 1, 2023 – Sep 30, 2024 Code page on GovTribe

The top 10 won 88% of FY2024 NAICS 325412 contract dollars

Ranking facts

Contract obligations
$10,085,282,033 Net of deobligations, by contracts coded NAICS 325412
Contractors
368 Parent companies with an obligation
Largest contractor
McKesson Corporation $8.38 billion, 76.5% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $8,381,750,200
Rank history: #1 in FY2021, #2 in FY2022, #1 in FY2023 and #1 in FY2025; unchanged since FY2023.
2
Roche Diabetes Care Inc Through Genentech Usa, Inc.
$396,999,520
Rank history: not on the FY2021–FY2022 lists, #89 in FY2023 and not on the FY2025 list; up 87 since FY2023.
3 $222,920,840
Rank history: #8 in FY2021, #11 in FY2022, #5 in FY2023 and #3 in FY2025; up 2 since FY2023.
4 $153,754,433
Rank history: not on the FY2021–FY2023 lists and #40 in FY2025; new.
5 $122,975,784
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
6 $91,119,397
Rank history: not on the FY2021 list, #13 in FY2022, #8 in FY2023 and #26 in FY2025; up 2 since FY2023.
7 $82,620,000
Rank history: #16 in FY2021, #14 in FY2022, #7 in FY2023 and #6 in FY2025; unchanged since FY2023.
8 $69,164,064
Rank history: not on the FY2021–FY2023 lists and #9 in FY2025; new.
9
Alvogen Group Inc. Through Alvogen, Inc.
$57,099,988
Rank history: not on the FY2021–FY2023 lists and #2 in FY2025; new.
10 $52,540,958
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; up 250 since FY2023.
11
Meridian Medical Technologies LLC
$36,600,000
Rank history: not on the FY2021–FY2023 lists and #11 in FY2025; new.
12 $33,009,853
Rank history: not on the FY2021–FY2023 lists and #90 in FY2025; new.
13 $32,713,775
Rank history: not on the FY2021–FY2023 lists and #12 in FY2025; new.
14 $28,180,072
Rank history: not on the FY2021 list, #27 in FY2022, #13 in FY2023 and #14 in FY2025; down 1 since FY2023.
15 $26,790,542
Rank history: not on the FY2021–FY2023 lists and #20 in FY2025; new.
16 $24,610,317
Rank history: #23 in FY2021, #24 in FY2022, #11 in FY2023 and #15 in FY2025; down 5 since FY2023.
17 $24,227,222
Rank history: #33 in FY2021, #36 in FY2022, #15 in FY2023 and not on the FY2025 list; down 2 since FY2023.
18 $22,201,974
Rank history: not on the FY2021 list, #16 in FY2022, #14 in FY2023 and #13 in FY2025; down 4 since FY2023.
19 $15,093,696
Rank history: #20 in FY2021, #23 in FY2022, #17 in FY2023 and not on the FY2025 list; down 2 since FY2023.
20 $14,958,069
Rank history: #34 in FY2021, #34 in FY2022, not on the FY2023 list and #65 in FY2025; returned.
21 $12,969,775
Rank history: #100 in FY2021, not on the FY2022–FY2023 lists and not on the FY2025 list; returned.
22 $11,190,536
Rank history: not on the FY2021–FY2023 lists and #24 in FY2025; new.
23 $10,093,323
Rank history: not on the FY2021–FY2023 lists and #31 in FY2025; up 97 since FY2023.
24 $10,091,475
Rank history: not on the FY2021 list, #28 in FY2022, #29 in FY2023 and not on the FY2025 list; up 5 since FY2023.
25 $9,745,158
Rank history: not on the FY2021–FY2023 lists and #36 in FY2025; new.
26 $8,133,605
Rank history: #24 in FY2021, #35 in FY2022, #26 in FY2023 and not on the FY2025 list; unchanged since FY2023.
27 $7,933,411
Rank history: #75 in FY2021, #33 in FY2022, #19 in FY2023 and not on the FY2025 list; down 8 since FY2023.
28
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$5,802,481
Rank history: #18 in FY2021, #20 in FY2022, #9 in FY2023 and not on the FY2025 list; down 19 since FY2023.
29 $5,550,111
Rank history: #36 in FY2021, not on the FY2022 list, #21 in FY2023 and not on the FY2025 list; down 8 since FY2023.
30 $5,520,606
Rank history: #31 in FY2021, #38 in FY2022, #18 in FY2023 and #37 in FY2025; down 12 since FY2023.
31 $5,468,579
Rank history: #5 in FY2021, #5 in FY2022, #43 in FY2023 and #23 in FY2025; up 12 since FY2023.
32 $4,147,309
Rank history: #50 in FY2021, #55 in FY2022, #27 in FY2023 and #32 in FY2025; down 5 since FY2023.
33 $3,767,731
Rank history: #65 in FY2021, #48 in FY2022, #32 in FY2023 and #33 in FY2025; down 1 since FY2023.
34
Walgreens Boots Alliance Inc. Through Walgreen Co.
$3,700,561
Rank history: not on the FY2021–FY2023 lists and #81 in FY2025; new.
35 $3,664,624
Rank history: #39 in FY2021, #41 in FY2022, #23 in FY2023 and #30 in FY2025; down 12 since FY2023.
36 $3,482,760
Rank history: #41 in FY2021, #61 in FY2022, #25 in FY2023 and not on the FY2025 list; down 11 since FY2023.
37 $3,157,223
Rank history: #48 in FY2021, #50 in FY2022, #70 in FY2023 and #38 in FY2025; up 33 since FY2023.
38 $3,133,081
Rank history: not on the FY2021–FY2023 lists and #29 in FY2025; new.
39 $3,106,500
Rank history: not on the FY2021 list, #99 in FY2022, #68 in FY2023 and #45 in FY2025; up 29 since FY2023.
40 $3,035,855
Rank history: #95 in FY2021, #25 in FY2022, #10 in FY2023 and not on the FY2025 list; down 30 since FY2023.
41 $2,929,036
Rank history: not on the FY2021–FY2022 lists, #77 in FY2023 and not on the FY2025 list; up 36 since FY2023.
42 $2,879,619
Rank history: #62 in FY2021, #53 in FY2022, #36 in FY2023 and not on the FY2025 list; down 6 since FY2023.
43 $2,861,412
Rank history: #70 in FY2021, #70 in FY2022, #49 in FY2023 and #75 in FY2025; up 6 since FY2023.
44 $2,589,730
Rank history: not on the FY2021–FY2023 lists and #43 in FY2025; new.
45 $2,242,678
Rank history: not on the FY2021 list, #92 in FY2022, #41 in FY2023 and not on the FY2025 list; down 4 since FY2023.
46 $2,241,168
Rank history: #49 in FY2021, #63 in FY2022, #35 in FY2023 and not on the FY2025 list; down 11 since FY2023.
47 $2,194,547
Rank history: #40 in FY2021, #47 in FY2022, #63 in FY2023 and not on the FY2025 list; up 16 since FY2023.
48 $2,185,359
Rank history: not on the FY2021 list, #89 in FY2022, #60 in FY2023 and #49 in FY2025; up 12 since FY2023.
49 $2,107,056
Rank history: not on the FY2021–FY2023 lists and #21 in FY2025; new.
50 $2,020,817
Rank history: #80 in FY2021, #69 in FY2022, #47 in FY2023 and #97 in FY2025; down 3 since FY2023.
51 $2,010,827
Rank history: not on the FY2021–FY2023 lists and #58 in FY2025; new.
52 $1,975,190
Rank history: #61 in FY2021, #64 in FY2022, #42 in FY2023 and #61 in FY2025; down 10 since FY2023.
53 $1,834,482
Rank history: #56 in FY2021, #43 in FY2022, #37 in FY2023 and not on the FY2025 list; down 16 since FY2023.
54 $1,785,334
Rank history: #59 in FY2021, #52 in FY2022, #40 in FY2023 and #44 in FY2025; down 14 since FY2023.
55 $1,710,640
Rank history: #37 in FY2021, #49 in FY2022, #30 in FY2023 and #83 in FY2025; down 25 since FY2023.
56 $1,688,407
Rank history: not on the FY2021 list, #67 in FY2022, #61 in FY2023 and #88 in FY2025; up 5 since FY2023.
57 $1,675,276
Rank history: not on the FY2021 list, #97 in FY2022, #62 in FY2023 and not on the FY2025 list; up 5 since FY2023.
58 $1,637,384
Rank history: not on the FY2021–FY2023 lists and #72 in FY2025; new.
59 $1,537,487
Rank history: not on the FY2021–FY2023 lists and #60 in FY2025; new.
60
Otsuka Holdings Co. Ltd. Through Otsuka America Pharmaceutical Inc.
$1,517,541
Rank history: not on the FY2021–FY2022 lists, #80 in FY2023 and #73 in FY2025; up 20 since FY2023.
61 $1,447,820
Rank history: #60 in FY2021, #66 in FY2022, #55 in FY2023 and #54 in FY2025; down 6 since FY2023.
62
Alexion Pharmaceuticals Inc 2 awardees
$1,441,918
Rank history: not on the FY2021–FY2023 lists and #96 in FY2025; new.
63 $1,438,308
Rank history: #53 in FY2021, #74 in FY2022, not on the FY2023 list and #82 in FY2025; up 73 since FY2023.
64 $1,357,944
Rank history: #29 in FY2021, #40 in FY2022, #38 in FY2023 and #55 in FY2025; down 26 since FY2023.
65 $1,321,816
Rank history: not on the FY2021–FY2022 lists, #33 in FY2023 and #51 in FY2025; down 32 since FY2023.
66 $1,307,972
Rank history: not on the FY2021 list, #91 in FY2022, not on the FY2023 list and #59 in FY2025; up 97 since FY2023.
67 $1,291,437
Rank history: #58 in FY2021, #42 in FY2022, #34 in FY2023 and not on the FY2025 list; down 33 since FY2023.
68 $1,233,156
Rank history: not on the FY2021–FY2023 lists and #39 in FY2025; new.
69 $1,133,332
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
70 $1,130,161
Rank history: #52 in FY2021, #71 in FY2022, #57 in FY2023 and #35 in FY2025; down 13 since FY2023.
71
Heyltex Corporation
$1,021,469
Rank history: not on the FY2021–FY2022 lists, #31 in FY2023 and not on the FY2025 list; down 40 since FY2023.
72 $1,014,964
Rank history: not on the FY2021–FY2023 lists and #99 in FY2025; up 148 since FY2023.
73 $978,666
Rank history: not on the FY2021–FY2022 lists, #73 in FY2023 and #74 in FY2025; unchanged since FY2023.
74
Jubilant Hollisterstier LLC
$946,735
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
75
Bracco U.S.a. Inc. Through Bracco Diagnostics Inc.
$941,987
Rank history: not on the FY2021–FY2023 lists and #41 in FY2025; new.
76 $938,112
Rank history: not on the FY2021–FY2022 lists, #90 in FY2023 and not on the FY2025 list; up 14 since FY2023.
77 $880,551
Rank history: not on the FY2021 list, #76 in FY2022, not on the FY2023 list and not on the FY2025 list; returned.
78 $811,832
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
79 $811,228
Rank history: #51 in FY2021, #46 in FY2022, #46 in FY2023 and not on the FY2025 list; down 33 since FY2023.
80 $798,008
Rank history: not on the FY2021–FY2022 lists, #64 in FY2023 and not on the FY2025 list; down 16 since FY2023.
81 $792,149
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
82 $788,819
Rank history: not on the FY2021–FY2023 lists and #66 in FY2025; up 60 since FY2023.
83 $782,009
Rank history: #35 in FY2021, #62 in FY2022, #45 in FY2023 and #52 in FY2025; down 38 since FY2023.
84
Jubilant Life Sciences Limited Through Jubilant Draximage Inc.
$774,807
Rank history: #96 in FY2021, #57 in FY2022, not on the FY2023 list and #95 in FY2025; up 27 since FY2023.
85
Seqirus USA Inc. 2 awardees, including CSL Behring L.L.C.
$751,265
Rank history: #19 in FY2021, #19 in FY2022, #51 in FY2023 and not on the FY2025 list; down 34 since FY2023.
86
Grifols Diagnostic Solutions Inc. Through Grifols USA LLC
$721,568
Rank history: #90 in FY2021, not on the FY2022 list, #71 in FY2023 and not on the FY2025 list; down 15 since FY2023.
87
American Regent Inc
$721,119
Rank history: not on the FY2021–FY2022 lists, #93 in FY2023 and #50 in FY2025; up 6 since FY2023.
88 $702,961
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
89 $701,995
Rank history: not on the FY2021–FY2022 lists, #94 in FY2023 and not on the FY2025 list; up 5 since FY2023.
90 $701,053
Rank history: not on the FY2021–FY2022 lists, #82 in FY2023 and #70 in FY2025; down 8 since FY2023.
91
Recordati Rare Diseases,
$679,416
Rank history: not on the FY2021 list, #81 in FY2022, #87 in FY2023 and not on the FY2025 list; down 4 since FY2023.
92 $667,625
Rank history: not on the FY2021–FY2023 lists and #64 in FY2025; new.
93 $659,087
Rank history: #71 in FY2021, #72 in FY2022, #58 in FY2023 and not on the FY2025 list; down 35 since FY2023.
94 $656,685
Rank history: not on the FY2021 list, #88 in FY2022, #79 in FY2023 and not on the FY2025 list; down 15 since FY2023.
95 $655,250
Rank history: not on the FY2021–FY2023 lists and #86 in FY2025; new.
96
Merz Pharmaceuticals LLC
$653,990
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
97
Horizon Therapeutics USA Inc.
$606,232
Rank history: #97 in FY2021, #60 in FY2022, #44 in FY2023 and not on the FY2025 list; down 53 since FY2023.
98
Low Cost RX LLC
$592,139
Rank history: not on the FY2021–FY2023 lists and not on the FY2025 list; new.
99 $576,301
Rank history: #14 in FY2021, not on the FY2022 list, #83 in FY2023 and not on the FY2025 list; down 16 since FY2023.
100 $541,012
Rank history: #92 in FY2021, not on the FY2022–FY2023 lists and not on the FY2025 list; up 65 since FY2023.
Show 75 more

100 of 368 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $11 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2024 ran Oct 1, 2023 – Sep 30, 2024. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2023. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2023 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 NAICS 325412 contractors in FY2024?

1. McKesson Corporation ($8.38B), 2. Roche Diabetes Care Inc ($397M), 3. Bavarian Nordic A / S ($223M), 4. Merck & Co. Inc. ($154M), 5. Emergent Biosolutions Canada Inc. ($123M), 6. Phlow Corp. ($91.1M), 7. Government of the United States ($82.6M), 8. Nighthawk Biosciences, Inc. ($69.2M), 9. Alvogen Group Inc. ($57.1M), 10. Roche Holdings Inc. ($52.5M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work